Evidence map›Paper›PMID 38947000›Full record

ArticleResearch square2024

A Microphysiological HHT-on-a-Chip Platform Recapitulates Patient Vascular Lesions.

Christopher C W Hughes, Jennifer Fang, Christopher Hatch, Jillian Andrejecsk, William Van Trigt, Damie Juat, Yu-Hsi Chen, Satomi Matsumoto, Abraham Lee

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Christopher C W HughesUniversity of California, Irvine.ORCID 0000-0002-3223-830X
Jennifer FangTulane University.ORCID 0000-0001-5703-2239
Christopher HatchUniversity of California-Irvine.
Jillian AndrejecskUniversity of California-Irvine.
William Van TrigtUniversity of California-Irvine.ORCID 0000-0003-3439-7352
Damie JuatUniversity of California-Irvine.
Yu-Hsi ChenUC, Irvine.
Satomi MatsumotoUniversity of California-Irvine.
Abraham LeeUniversity of California, Irvine.ORCID 0000-0001-8378-6616

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Training Program in Cardiovascular Applied Research and EntrepreneurshipT32HL116270 · NHLBI · UNIVERSITY OF CALIFORNIA-IRVINE · PI HUGHES, CHRISTOPHER C. W. · 2013 to 2022
$1.6M
NCATS NIH HHS UL1 TR001414NHLBI NIH HHS T32 HL116270
6 · The paper itself

Abstract

Hereditary Hemorrhagic Telangiectasia (HHT) is a rare congenital disease in which fragile vascular malformations (VM) - including small telangiectasias and large arteriovenous malformations (AVMs) - focally develop in multiple organs. There are few treatment options and no cure for HHT. Most HHT patients are heterozygous for loss-of-function mutations affecting Endoglin (ENG) or Alk1 (ACVRL1); however, why loss of these genes manifests as VMs remains poorly understood. To complement ongoing work in animal models, we have developed a fully human, cell-based microphysiological model based on our Vascularized Micro-organ (VMO) platform (the HHT-VMO) that recapitulates HHT patient VMs. Using inducible

Indexed as

Alk1arteriovenous malformationAVMBiological SciencesCell Biologyfluid shear stressHereditary Hemorrhagic TelangiectasiaHHTmicrophysiological systemsmicrovasculatureMPS systemsorgan-on-a-chiptelangiectasiavascular malformationvessel-on-a-chip

Identifiers

PMID38947000
PMCPMC11213165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.